Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB-G3B7-NK
- Development stage
- Phase 2
- Lead developer
- Beijing Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EB-G3B7-NK is an allogeneic, dual-target chimeric antigen receptor (CAR) natural killer (NK) cell therapy developed by Beijing Biotech for the treatment of advanced hepatocellular carcinoma (HCC). The therapy is engineered to express CARs targeting both Glypican-3 (GPC3), a well-established antigen in HCC, and CD276 (B7-H3), an immune checkpoint molecule often overexpressed in the tumor microenvironment. By targeting two antigens, EB-G3B7-NK aims to minimize antigen escape and enhance therapeutic efficacy against heterogeneous tumors. The cells are donor-derived (allogeneic) and administered intravenously following lymphodepleting chemotherapy with fludarabine and cyclophosphamide.
- Other names
- allogeneic dual-target GPC3/B7-H3 CAR-NK cellsEB-G3B7-NK dual-target CAR-NK cellsEB-G-3B7-NK dual-target CAR-NK cellsEB-G 3B7-NK dual-target CAR-NK cells
02
Targets
B7-H3GPC3 (Glypican-3)
Beyond the preview
Go deeper on EB-G3B7-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB-G3B7-NK.